Daxor (DXR) Stock Price, News & Analysis

Company Overview

Daxor Corporation (NYSE American: DXR) is a medical technology company specializing in diagnostic solutions for the measurement of blood volume. The company’s proprietary BVA-100 and BVA-200 systems utilize radiolabeled albumin tracers to provide clinicians with precise determinations of total blood volume, plasma volume and red blood cell volume. By offering quantitative assessments rather than estimations, Daxor’s platform aims to improve clinical decision-making for conditions that involve fluid balance and hemodynamic status.

In addition to its analytical instruments, Daxor maintains a CLIA-certified laboratory service that processes in-vitro diagnostic reagents and delivers detailed blood volume reports directly to healthcare providers. The company supplies reagent kits, disposables and software tools to support hospital laboratories, outpatient clinics and research institutions. Its diagnostic applications span cardiology (heart failure management), nephrology (renal dysfunction) and hepatology (cirrhosis evaluation), and the technology has also been employed in clinical trials and oncology studies.

Headquartered in New York, Daxor serves customers across the United States and holds CE Mark certification for its systems in Europe. The company was incorporated in Delaware in the late 1990s and has been advancing blood volume measurement technology ever since. By combining on-site instrumentation with centralized laboratory services, Daxor positions itself as a specialist in precision fluid management diagnostics without relying on indirect estimation methods.

Key Stats

• Today's Range: $11.40 to $11.66
• 50-Day Range: $9.09 to $11.66
• 52-Week Range: $6.55 to $11.70
• Volume: 6,000 shs
• Average Volume: 14,595 shs
• Market Capitalization: $55.27 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

DXR Stock Analysis - Frequently Asked Questions

How have DXR shares performed this year?

Daxor's stock was trading at $7.9350 on January 1st, 2025. Since then, DXR shares have increased by 46.9% and is now trading at $11.66.

How do I buy shares of Daxor?

Shares of DXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Daxor own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Daxor investors own include Inovio Pharmaceuticals (INO), Pfizer (PFE), Gilead Sciences (GILD), Novavax (NVAX), iBio (IBIO), CRISPR Therapeutics (CRSP) and Dynavax Technologies (DVAX).

Company Calendar

• Today: 9/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Medical Instruments & Supplies
• Sub-Industry: Medical Equipment
• Current Symbol: NYSEAMERICAN:DXR
• Previous Symbol: NYSE:DXR
• CIK: 27367
• Web: www.daxor.com
• Phone: (865) 425-0555
• Fax: 212-244-0806
• Employees: 37
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 4,740,000
• Free Float: 1,866,000
• Market Cap: $55.27 million
• Optionable: Not Optionable
• Beta: -0.50